Chris Kemmerer

Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA.

Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA.

Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA.

Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA.

Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA.

Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA.

Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA.

Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA.

Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA.

Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA.

Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA.

Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA.

Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA.

Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA.

Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA.

Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA.

Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA.

Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA.